Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer—Results from the AGMT GASTRIC-5 Registry
出版年份 2020 全文链接
标题
Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer—Results from the AGMT GASTRIC-5 Registry
作者
关键词
-
出版物
Journal of Clinical Medicine
Volume 9, Issue 4, Pages 935
出版商
MDPI AG
发表日期
2020-04-03
DOI
10.3390/jcm9040935
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
- (2019) Salah-Eddin Al-Batran et al. LANCET
- Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
- (2019) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment Algorithm for Patients With Gastric Adenocarcinoma: An Austrian Consensus on Systemic Therapy
- (2019) EWALD WÖLL et al. ANTICANCER RESEARCH
- Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis
- (2018) Emil ter Veer et al. INTERNATIONAL JOURNAL OF CANCER
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018
- (2018) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study
- (2018) Josep Tabernero et al. LANCET ONCOLOGY
- Association of HER2 gene amplification and tumor progression in early gastric cancer
- (2018) Kazuki Kanayama et al. VIRCHOWS ARCHIV
- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Kohei Shitara et al. LANCET ONCOLOGY
- Intratumoral HER2 heterogeneity in early gastric carcinomas: potential bias in therapeutic management
- (2018) Antonio Ieni et al. VIRCHOWS ARCHIV
- HER2 testing in gastric cancer: results of a German expert meeting
- (2017) Florian Lordick et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- Clinical relevance and concordance of HER2 status in local and central testing—an analysis of 1581 HER2-positive breast carcinomas over 12 years
- (2017) Berit M Pfitzner et al. MODERN PATHOLOGY
- A potential pitfall in evaluating HER2 immunohistochemistry for gastric signet ring cell carcinomas
- (2017) Chang Gok Woo et al. PATHOLOGY
- Discordance Rate of HER2 Status in Primary Gastric Cancer and Synchronous Lymph Node Metastases: Its Impact on Therapeutic Decision and Clinical Management
- (2017) A. Ieni et al. PATHOLOGY & ONCOLOGY RESEARCH
- Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) E. C. Smyth et al. ANNALS OF ONCOLOGY
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1)
- (2016) Sook Ryun Park et al. EUROPEAN JOURNAL OF CANCER
- Concordance of HER2 status between local and central review in gastric and gastroesophageal junction cancers: A French observational study of 394 specimens (HERable study).
- (2016) Genevieve Monges-Ranchin et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial
- (2016) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib
- (2016) Michael F. Press et al. MOLECULAR CANCER THERAPEUTICS
- HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic Disease
- (2016) Michelina Amato et al. PATHOLOGY & ONCOLOGY RESEARCH
- Metastatic spread in patients with gastric cancer
- (2016) Matias Riihimäki et al. Oncotarget
- Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge
- (2015) Simon Pernot WORLD JOURNAL OF GASTROENTEROLOGY
- HER2 Directed Therapy for Gastric/Esophageal Cancers
- (2014) Elizabeth Won et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance
- (2014) Shih-Chiang Huang et al. Gastric Cancer
- Discordance Rate of HER2 Status in Primary Gastric Carcinomas and Synchronous Lymph Node Metastases: A Multicenter Retrospective Analysis
- (2014) Antonio Ieni et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study
- (2014) Taroh Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Clinicopathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature
- (2014) Ji-wang Liang et al. TUMOR BIOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- HER2 Status in Gastric and Gastroesophageal Junction Cancer Assessed by Local and Central Laboratories: Chinese Results of the HER-EAGLE Study
- (2013) Dan Huang et al. PLoS One
- HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature
- (2012) Jan Trøst Jørgensen et al. Journal of Cancer
- Attributable causes of cancer in Japan in 2005—systematic assessment to estimate current burden of cancer attributable to known preventable risk factors in Japan
- (2011) M. Inoue et al. ANNALS OF ONCOLOGY
- Evaluation of HER2 Protein Expression in Gastric Carcinomas: Comparative Analysis of 1414 Cases of Whole-Tissue Sections and 595 Cases of Tissue Microarrays
- (2011) Kab Choong Kim et al. ANNALS OF SURGICAL ONCOLOGY
- Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens
- (2011) Jiyuan Yang et al. CELL BIOCHEMISTRY AND BIOPHYSICS
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
- (2009) J D Barros-Silva et al. BRITISH JOURNAL OF CANCER
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started